Additional file 1: Table S1. of Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study

Duration of exposure to fingolimod in patients entering the extension study. Table S2. Plasma levels of liver enzymes at core study baseline and in the extension study. Table S3. Proportion of patients with normal and elevated levels of liver enzymes. Table S4. Proportion of patients with normal and decreased levels of hematological parameters. (DOCX 35 kb

Additional file 2: of Latitude and HLA-DRB1*04:05 independently influence disease severity in Japanese multiple sclerosis: a cross-sectional study

Table S1. Phenotypic frequencies of HLA-DPB1 alleles in patients with MS. Table S2. Phenotypic frequencies of HLA-DRB1 alleles in MS patients from northern Japan. Table S3. Phenotypic frequencies of HLA-DRB1 alleles in MS patients from southern Japan. Table S4. Phenotypic frequencies of HLA-DRB1 alleles in HCs. Table S5. Demographic features of patients with MS, excluding SPMS, according to region. Table S6. Comparison of MS demographic features between northern and southern patients using clinical data from southern patients followed up until January 2013. Table S7. Comparison of MS demographic features between northern and southern patients using clinical data from southern patients followed up until January 2013, excluding SPMS. Table S8. Comparison of MSSS between MS patients with and without Barkhof brain lesions, and between those with and without CSF IgG abnormalities. Table S9. Comparison of clinical features in patients with MS according to the presence or absence of HLA-DRB1*15:01. Table S10. Clinical characteristics of MS patients with the HLA-DRB1*15:01 allele. (DOCX 54 kb